DRUGapprovedsmall molecule
SIMVASTATIN
Approved indications
cholesterol-hyperlipidemia
Related claims (19)
| Type | Predicate | Conf | Source |
|---|---|---|---|
| drug efficacy | Pretreatment with geranylgeraniol partly reversed the inhibitory effect of simvastatin on LY83583‑induced CyPA secretion in cultured VSMCs (in vitro). | 65% | 28983618 |
| pathway membership | Simvastatin neuroprotection may be related to a variety of signaling pathways including Rho-kinase (ROCK). | 65% | 20493175 |
| drug efficacy | Simvastatin treatment (20mg/kg, bolus subcutaneous injection) significantly improved clinical function (rabbit model). | 65% | 20493175 |
| drug efficacy | GGTI‑298 and KD025 [a selective Rho‑associated protein kinase 2 (ROCK2) inhibitor] mimicked the inhibitory effect of simvastatin on CyPA secretion in cultured VSMCs (in vitro). | 59% | 28983618 |
| drug efficacy | Simvastatin treatment (20mg/kg, bolus subcutaneous injection) increased the P(50) by 143% when administered 1 hour following embolization (rabbit model). | 59% | 20493175 |
| drug target | Fasudil and simvastatin effectively inhibited 3-NP-induced behavioral, biochemical, and histological changes through inhibition of ROCK activity (in rat model). | 59% | 26169112 |
| pathway membership | The present study highlights a significant role of ROCK/p-Akt/eNOS pathway in the protective effects of fasudil and simvastatin on neurotoxicity and mitochondrial dysfunction induced by 3-NP (in rat model). | 59% | 26169112 |
| pathway membership | The present study highlights a significant role of ROCK/p-Akt/eNOS pathway in the protective effects of fasudil and simvastatin on mitochondrial dysfunction induced by 3-NP (in rat model). | 59% | 26169112 |
| protein interaction | There may be an interaction between simvastatin treatment and the ROCK signaling pathway (rabbit model). | 59% | 20493175 |
| drug target | Simvastatin, which inhibits RhoA, inhibits ROCK activity in Th17 cells (in vitro). | 59% | 28283529 |
| drug efficacy | Simvastatin could be safely administered with tPA to improve clinical scores (rabbit model). | 53% | 20493175 |
| drug efficacy | Simvastatin may inhibit reactive oxygen species‑induced cyclophilin A (CyPA) release from vascular smooth muscle cells (VSMCs) (in vitro). | 53% | 28983618 |
| drug efficacy | Fasudil and simvastatin effectively inhibited 3-NP-induced histological changes (in rat model). | 53% | 26169112 |
| drug efficacy | Fasudil and simvastatin effectively inhibited 3-NP-induced behavioral changes (in rat model). | 53% | 26169112 |
| drug efficacy | Fasudil and simvastatin effectively inhibited 3-NP-induced biochemical changes (in rat model). | 53% | 26169112 |
| drug efficacy | VSMCs from simvastatin‑treated rats secreted a decreased amount of CyPA compared with VSMCs from hypertensive rats (mouse model). | 53% | 28983618 |
| drug efficacy | When fasudil was administered 30 minutes before simvastatin (given at 1 hour), there was an additional significant (p=0.0217) synergistic increase in behavioral function (rabbit model). | 51% | 20493175 |
| drug efficacy | Simvastatin administration for 4, 8 and 12 weeks diminished the increased expression of CD147, phosphorylated‑ERK1/2, cyclin D1, cyclin A, and cyclin E, as observed in the hypertensive group (mouse model). | 51% | 28983618 |
| drug efficacy | Simvastatin decreases IL-17 and IL-21 production by purified SLE T cells or Th17 cells (in vitro). | 45% | 28283529 |
Off-Target Findings (0)
No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.